Improving smoking cessation treatments for HIV-positive smokers
Testing Novel Pharmacogenetic and Adherence Optimization Treatments to Improve the Effectiveness of Smoking Cessation Treatments for Smokers with HIV
['FUNDING_R01'] · UNIVERSITY OF PENNSYLVANIA · NIH-10977323
This study is looking at new ways to help people with HIV/AIDS quit smoking by personalizing their treatment based on their genetics and using a special support program to tackle the unique challenges they face, making it easier for them to succeed in quitting.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PENNSYLVANIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-10977323 on ClinicalTrials.gov |
What this research studies
This research investigates new methods to enhance smoking cessation treatments specifically for individuals living with HIV/AIDS. It focuses on personalizing medication choices based on genetic factors that affect nicotine metabolism and improving adherence to treatment plans. By utilizing a novel intervention called Managed Problem Solving (MAPS), the study aims to address the unique challenges faced by smokers with HIV, ultimately increasing their chances of quitting successfully.
Who could benefit from this research
Good fit: Ideal candidates for this research are smokers who are living with HIV/AIDS and seeking assistance to quit smoking.
Not a fit: Patients who do not smoke or are not living with HIV/AIDS may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve smoking cessation rates among HIV-positive individuals, leading to better overall health outcomes.
How similar studies have performed: Previous research has shown promise in personalizing smoking cessation treatments based on genetic factors, indicating that this approach could be effective.
Where this research is happening
PHILADELPHIA, UNITED STATES
- UNIVERSITY OF PENNSYLVANIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SCHNOLL, ROBERT ADAM — UNIVERSITY OF PENNSYLVANIA
- Study coordinator: SCHNOLL, ROBERT ADAM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus